Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
367 Qi, Y
Dual-Agonist Comparisons Tirzepatide (found in medications like Mounjaro) targets two receptors: GLP-1 and GIP
Personalised Care We provide thorough assessments to develop customised treatment plans for optimal results
GLP-1/glucagon co-agonists The development of these unimolecular formulations targeting both GLP-1 and glucagon receptors enhances the anorectic effect of GLP-1, provides a lipolytic and lipogenesis-inhibiting effect (Table 2)particularly at the hepatic leveland promotes thermogenic activity, thereby facilitating weight reduction and the treatment of MASLD.1,5,35 Survodutide generates dose-dependent weight reduction of up to 14.9% in 46 weeks.49 It is shown to be effective in reducing liver fat and improving MASH in up to 62% of participants treated with weekly injection of 4.8 mg
Lancet 368: 1696705 4
It should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
US$ 27.93
US$ 24.97
US$ 26.76
US$ 29.58
US$ 25.40
US$ 29.35
US$ 25.71
